Medicare Announces Lower Prices for 10 Common Drugs: Details and Costs

Last week, Medicare revealed that it will lower the prices of 10 popular drugs. This is the first time the government has negotiated to reduce the costs of some of the priciest and most frequently used medications in the Medicare program. These drugs treat conditions like heart disease, diabetes, and cancer.

If these new prices had been in place last year, Medicare would have saved about $6 billion, or 22%, across these 10 drugs. People with Medicare, who often share part of the drug costs, could save around $1.5 billion in out-of-pocket expenses when the new prices start.

However, the lower prices won’t take effect until January 1, 2026, for those with Medicare Part D prescription coverage. Negotiations for 15 more drugs will begin soon after, with changes expected in 2027. The agency plans to negotiate prices for additional drugs each year.

Here are the new prices for a 30-day supply of the drugs:

• Eliquis (blood thinner): $231, down from $521
• Enbrel (rheumatoid arthritis): $2,355, down from $7,106
• Entresto (heart failure): $295, down from $628
• Farxiga (diabetes, heart failure, chronic kidney disease): $178, down from $556
• Fiasp and NovoLog (diabetes): $119, down from $495
• Imbruvica (blood cancers): $9,319, down from $14,934
• Januvia (diabetes): $113, down from $527
• Jardiance (diabetes): $197, down from $573
• Stelara (psoriasis and Crohn’s disease): $4,695, down from $13,836
• Xarelto (blood thinner): $197, down from $517

These new prices don’t directly compare to what Medicare and its enrollees previously paid because the list price does not include any rebates or discounts offered by drug companies.